Pathogenetic rationale for the use of cell therapy in lung injury associated with SARS-CoV-2
https://doi.org/10.35401/2500-0268-2020-18-2-69-78
Abstract
Acute respiratory disease COVID-19 caused by the SARS-CoV-2 coronavirus demonstrate weak clinical manifestation in most patients. However, pneumonia and acute respiratory distress syndrome in some cases may cause serious problems due to the lack of effective etiotropic and pathogenetic therapy. Presumably, SARS-CoV-2 leads to the delayed type I interferon activation and loss of control over virus replication in the early stages of infection, which is why the adaptive CD8+T-cell response must be controlled to avoid the development of pulmonary pathology. These data should be taken into account when developing strategies for COVID-19 therapy. Mesenchymal stem cells therapy serves as possible treatment opportunity for severe forms of the disease due to their homing, pronounced anti-inflammatory and antifibrotic properties. It was found that in viral infections, including COVID-19, mesenchymal stem cells can synthesize antiviral defense mediators under the influence of interferon causing resistance to viruses. Thus, mesenchymal stem cells are able to provide comprehensive anti-inflammatory protection, which leads to clinical improvement in patients with COVID-19.
About the Authors
A. I. Stukan
Clinical Oncology Center no. 1; Kuban State Medical University
Russian Federation
Russian Federation
Anastasia I. Stukan, Cand. of Sci. (Med.), Oncologist, Oncology Department no. 9; Assistant Professor, Department of Oncology with the Course of Thoracic Surgery, Faculty of Advanced Training and Professional Retraining of Specialists
I. V. Gilevich
Kuban State Medical University; Scientific Research Institute – Ochapovsky Regional Clinical Hospital no. 1
Russian Federation
Russian Federation
Irina V. Gilevich, Cand. of Sci. (Med.), Head of the Laboratory for Development and Study of New Treatment Technologies; Assistant Professor, Department of Oncology with the Course of Thoracic Surgery, Faculty of Advanced Training and Professional Retraining of Specialists
140, Rossiyskaya str., Krasnodar, 350029
V. A. Porhanov
Kuban State Medical University; Scientific Research Institute – Ochapovsky Regional Clinical Hospital no. 1
Russian Federation
Russian Federation
Vladimir A. Porhanov, Head of the Department of Oncology with the Course of Thoracic Surgery, Faculty of Advanced Training and Professional Retraining of Specialists, Academician of the Russian Academy of Sciences, Dr. of Sci. (Med.), Professor, Chief Doctor
V. N. Bodnya
Kuban State Medical University; Scientific Research Institute – Ochapovsky Regional Clinical Hospital no. 1
Russian Federation
Russian Federation
Vadim N. Bodnya, Associate Professor, Department of Oncology with the Course of Thoracic Surgery, Faculty of Advanced Training and Professional Retraining of Specialists; Cand. of Sci. (Med.), Thoracic Surgeon, Thoracic Surgery Department no. 2
References
1. Del Rio C, Malani PN. 2019 Novel Coronavirus – Important Information for Clinicians. JAMA. 2020;323:1039–40. PMID: 32022836. doi:10.1001/jama.2020.1490
2. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–13. PMID: 32007143. PMCID: PMC135076. doi:10.1016/s0140-6736(20)30211-7
3. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11:222. PMID: 31924756. PMCID: PMC6954302. doi:10.1038/s41467-019-13940-6
4. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020.28;395:1033–4. PMID: 32192578. doi:10.1016/s0140-6736(20)30628-0
5. Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD. How will country-based mitigation measures influence the course of the COVID-19 epidemic? Lancet. 2020;395:931–4. PMID: 32164834. PMCID: PMC7158572. doi:10.1016/s0140-6736(20)30567-5
6. Zhao RC. Stem cell-based therapy for coronavirus disease 2019. Stem Cells Dev. [Online ahead of print]. 2020. [Posted 2020 Apr 7]. PMID: 32292113. doi:10.1089/scd.2020.0071
7. Xiong Yo, Liu Yu, Cao L, et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg Microbes Infect. 2020;9:761–70. PMID: 32228226. PMCID: PMC7170362. doi:10.1080/22221751.2020.1747363
8. Coronavirus disease 2019 (COVID-19). Situation Report – 30. Data as reported by 19 February 2020. World Health Organization. [Internet]. [Cited 2020 May 11]. Available from: https://www.who.int/docs/default-source/coronaviruse/situationreports/20200219-sitrep-30-covid-19.pdf?sfvrsn=3346b04f_2
9. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–33. PMID: 31978945. PMCID: PMC7092803. doi:10.1056/nejmoa2001017
10. Prompetchara Е, Ketloy Сh, Palaga Т. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38:1–9. PMID: 32105090. doi:10.12932/AP-200220-0772
11. De Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14:523–34. PMID: 27344959. PMCID: PMC7097822. doi:10.1038/nrmicro.2016.81
12. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39:529–39. PMID: 28466096. PMCID: PMC7079893. doi:10.1007/s00281-017-0629-x
13. Kindler E, Thiel V, Weber F. Interaction of SARS and MERS coronaviruses with the antiviral interferon response. Adv Virus Res. 2016;96:219–43. PMID: 27712625. PMCID: PMC7112302. doi:10.1016/bs.aivir.2016.08.006
14. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–74. PMID: 32007145. PMCID: PMC7159086. doi:10.1016/s0140-6736(20)30251-8
15. Huang Ch, Wang Ye, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. PMID: 31986264. PMCID: PMC7159299. doi:10.1016/s0140-6736(20)30183-5
16. Liu WJ, Zhao M, Liu K, et al. T-cell immunity of SARS-CoV: implications for vaccine development against MERS-CoV. Antiviral Res. 2017;137:82–92. PMID: 27840203. PMCID: PMC7113894. doi:10.1016/j.antiviral.2016.11.006
17. Zhou P, Yang XL, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–3. PMID: 32015507. PMCID: PMC7095418. doi:10.1038/s41586-020-2012-7
18. Guan W-J, Ni Zh-Yi, Hu Yu, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–20. PMID: 32109013. PMCID: PMC7092819. doi:10.1056/NEJMoa2002032
19. Atluri S, Manchikanti L, Hirsch JA. Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically ill COVID-19 patients: the case for compassionate use. Pain Physician. 2020;23:E71–E83. PMID: 32214286.
20. De Becker A, van Riet I. Homing and migration of mesenchymal stromal cells: how to improve the efficacy of cell therapy? World J Stem Cells. 2016;8:73–87. PMID: 27022438. PMCID: PMC4807311. doi:10.4252/wjsc.v8.i3.73
21. Holodenko IV, Konieva AA, Holodenko RV, Yarygin KN. Molecular and cellular mechanisms of migration and homing of intravenously transplanted mesenchymal stem cells. In: VA Tkachuk, ed. Stvolovye kletki i regenerativnaya meditsina: sbornik statey = Stem Cells and Regenerative Medicine: a Collection of Articles. 2014:196–218. (In Russ.)
22. Richardson SM, Kalamegam G, Pushparaj PN, et al. Mesenchymal stem cells in regenerative medicine: focus on articular cartilage and intervertebral disc regeneration. Methods. 2016;99:69–80. PMID: 26384579. doi:10.1016/j.ymeth.2015.09.015
23. Bieback K, Wuchter P, Besser D, et al. Mesenchymal stromal cells (MSCs): science and f(r)iction. J Mol Med (Berl). 2012;90:773–82. PMID: 22648521. doi:10.1007/s00109-012-0915-y
24. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9:11–5. PMID: 21726829. PMCID: PMC3144500. doi:10.1016/j.stem.2011.06.008
25. Huang Yo-C, Parolini O, Deng L. The potential role of microvesicles in mesenchymal stem cell-based therapy. Stem Cells Dev. 2013;22:841–4. PMID: 23216256. doi:10.1089/scd.2012.0631
26. Mueller M, Wolfs TGA, Schoeberlein A, Gavilanes AWD, Surbek D, Kramer BW. Mesenchymal stem/stromal cells – a key mediator for regeneration after perinatal morbidity? Mol Cell Pediatr. 2016;3:6. PMID: 26869264. PMCID: PMC4751100. doi:10.1186/s40348-016-0034-x
27. Vorotnikov AV, Suzdaltseva YuG, Rubtsov YuP, et al. Directed migration and mesenchymal progenitor cells: participation in inflammation, tissue repair and regeneration. In: VA Tkachuk, ed. Stvolovye kletki i regenerativnaya meditsina: sbornik statey = Stem Cells and Regenerative Medicine: a Collection of Articles. 2012:57–91. (In Russ.)
28. Conese M, Carbone A, Castellani S, Di Giola S. Paracrine effects and heterogeneity of marrow-derived stem/progenitor cells: relevance for the treatment of respiratory diseases. Cells Tissues Organs. 2013;197:445–73. PMID: 23652321. doi:10.1159/000348831
29. Xu T, Zhang Yu, Chang P, Gong Sh, Shao L, Dong L. Mesenchymal stem cell-based therapy for radiation-induced lung injury. Stem Cell Res Ther. 2018;9:18. PMID: 29386045. PMCID: PMC5793340. doi:10.1186/s13287-018-0776-6
30. Murphy MB, Moncivais K, Caplan AI. Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp Mol Med. 2013;45:e54. PMID: 24232253. PMCID: PMC3849579. doi:10.1038/emm.2013.94
31. Ben-Ami E, Miller A, Berrih-Aknin S. T-cells from autoimmune patients display reduced sensitivity to immunoregulation by mesenchymal stem cells: role of IL-2. Autoimmun Rev. 2014;13:187–96. PMID: 24121085. doi:10.1016/j.autrev.2013.09.007
32. Khoury M, Cuenca J, Cruz FF, Figueroa FE, Rocco PRM, Weiss DJ. Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19. [Online ahead of print]. Eur Respir J. [Posted 2020 Apr 7]. PMID: 32265310. PMCID: PMC7144273. doi:10.1183/13993003.00858-2020
33. Spees JL, Lee RH, Gregory CA. Mechanisms of mesenchymal stem/stromal cell function. Stem Cell Res Ther. 2016;7:125. PMID: 27581859. PMCID: PMC5007684. doi:10.1186/s13287-016-0363-7
34. Usunier B, Benderitter M, Tamarat R, Chapel A. Management of fibrosis: the mesenchymal stromal cells breakthrough. Stem Cells Int. 2014;2014:340257. PMID: 25132856. PMCID: PMC4123563. doi:10.1155/2014/340257
35. Li X, Yue Sh, Luo Z. Mesenchymal stem cells in idiopathic pulmonary fibrosis. Oncotarget. 2017;8:102600–16. PMID: 29254275. PMCID: PMC5731985. doi:10.18632/oncotarget.18126
36. Ono M, Ohkouchi Sh, Kanehira M, et al. Mesenchymal stem cells correct inappropriate epithelial-mesenchyme relation in pulmonary fibrosis using stanniocalcin-1. Mol Ther. 2015;23:549–60. PMID: 25373521. PMCID: PMC4351453. doi:10.1038/mt.2014.217
37. Pourgholaminejad A, Aghdami N, Baharvand H, Moazzeni SM. The effect of pro-inflammatory cytokines on immunophenotype, differentiation capacity and immunomodulatory functions of human mesenchymal stem cells. Cytokine. 2016;85:51–60. PMID: 27288632. doi:10.1016/j.cyto.2016.06.003
38. Bari E, Ferrarotti I, Saracino L, Perteghella S, Torre ML, Corsico AG. Mesenchymal stromal cell secretome for severe COVID-19 infections: premises for the therapeutic use. Cells. 2020;9:E924. PMID: 32283815. doi:10.3390/cells9040924
39. Laffey JG, Matthay MA. Fifty years of research in ARDS. Cell-based therapy for acute respiratory distress syndrome. Biology and potential therapeutic value. Am J Respir Crit Care Med. 2017;196:266–73. PMID: 28306336. PMCID: PMC5549868. doi:10.1164/rccm.201701-0107CP
40. Li Ya, Xu J, Shi W, et al. Mesenchymal stromal cell treatment prevents H9N2 avian influenza virus-induced acute lung injury in mice. Stem Cell Res Ther. 2016;7:159. PMID: 27793190. PMCID: PMC5084318. doi:10.1186/s13287-016-0395-z
41. Chan MCW, Kuok DIT, Leung CYH, et al. Human mesenchymal stromal cells reduce influenza A H5N1-associated acute lung injury in vitro and in vivo. Proc Natl Acad Sci U S A. 2016;113:3621–6. PMID: 26976597. PMCID: PMC4822574. doi:10.1073/pnas.1601911113
42. Loy H, Kuok DIT, Hui KPY, et al. Therapeutic implications of human umbilical cord mesenchymal stromal cells in attenuating influenza A(H5N1) virus-associated acute lung injury. J Infect Dis. 2019;219:186–96. PMID: 3008507. PMCID: PMC6306016. doi:10.1093/infdis/jiy478
43. Khatri M, Saif YeM. Influenza virus infects bone marrow mesenchymal stromal cells in vitro: implications for bone marrow transplantation. Cell Transplant. 2013;22:461–8. PMID: 23006541. doi:10.3727/096368912X656063
44. Bao L, Deng W, Huang B, et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. [Online ahead of print]. Nature. [Posted 2020 May 7]. PMID: 32380511. doi:10.1101/2020.02.07.939389
45. Bao L, Deng W, Gao H, et al. Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. [Online ahead of print]. BioRxiv. [Posted 2020 March 14]. doi:10.1101/2020.03.13.990226
46. Jin Yi-H, Cai L, Cheng Zh-Sh, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020;7:4. PMID: 32029004. PMCID: PMC7003341. doi:10.1186/s40779-020-0233-6
47. Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22:824–33. PMID: 29859173. PMCID: PMC6434696. doi:10.1016/j.stem.2018.05.004
48. Matthay MA, Calfee CS, Zhuo H, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med. 2019;7:154–62. PMID: 30455077. doi:10.1016/S2213-2600(18)30418-1
49. Liang B, Chen J, Li T, et al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells. [Online ahead of print]. ChinaXiv. [Posted 27 Feb 2020]. Available from: http://chinaxiv.org/abs/202002.00084
50. Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2–mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11:216–28. PMID: 32257537. PMCID: PMC7069465. doi:10.14336/ad.2020.0228
Review
For citations:
Stukan A.I., Gilevich I.V., Porhanov V.A., Bodnya V.N. Pathogenetic rationale for the use of cell therapy in lung injury associated with SARS-CoV-2. Innovative Medicine of Kuban. 2020;(2):69-78. (In Russ.) https://doi.org/10.35401/2500-0268-2020-18-2-69-78
Views:
849
Email this article 
